Anacor $30 million loan pegged to clinical progress on antifungal returned by Merck
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals has agreed to a loan agreement led by Oxford Finance Corporation and partnered with Horizon Technology Finance Corporation to provide up to $30 million, a further capital injection that allows the company to take forward its lead drug reacquired from Merck.